Transgenomic, Inc. (NASDAQ:TBIO) , a global biotechnology company
advancing personalized medicine in cardiology, oncology, and inherited
diseases through advanced diagnostic tests and clinical and research
services, today announced a research agreement with the University of
Melbourne to conduct additional clinical validation studies of its
Multiplexed ICE COLD-PCR TM (MX-ICP) technology.
for - Transgenomic and University of Melbourne Collaborate to Further Validate Ability of Multiplexed ICE COLD-PCRTM to Enable Personalized Cancer Treatment investment picks